Literature DB >> 8032050

Invasive pulmonary aspergillosis associated with low dose methotrexate therapy for rheumatoid arthritis: a case report of treatment with itraconazole.

S O'Reilly1, P Hartley, M Jeffers, E Casey, L Clancy.   

Abstract

Opportunistic infections complicating low dose methotrexate therapy are rare, consisting predominantly of Pneumocystis carinii pneumonia. We report a case of invasive pulmonary aspergillosis which developed in a patient being treated for seropositive rheumatoid arthritis with low dose methotrexate (5-7.5 mg weekly) for 8 years. The patient was successfully treated with itraconazole 200 mg daily for 6 months. This case adds to the growing evidence implicating low dose methotrexate with opportunistic infections and should heighten clinical awareness in patients on this treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032050     DOI: 10.1016/0962-8479(94)90046-9

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  4 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Pulmonary coinfection by Pneumocystis carinii and Aspegillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate.

Authors:  M Mariñosa; A Soler; X Nogués; J Pedro-Botet
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

3.  Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.

Authors:  J D Greenberg; G Reed; J M Kremer; E Tindall; A Kavanaugh; C Zheng; W Bishai; M C Hochberg
Journal:  Ann Rheum Dis       Date:  2009-04-08       Impact factor: 19.103

4.  Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy.

Authors:  Ariane Leboime; Jean-Marie Berthelot; Yannick Allanore; Lama Khalil-Kallouche; Philippe Herman; Philippe Orcel; Frédéric Lioté
Journal:  Arthritis Res Ther       Date:  2009-11-03       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.